陈煜森;曾志良;林智君;冼文川;钟望涛;赵斌;许志恩;

• 1:广东医学院附属医院神经内科
• 2:广东东莞市太平人民医院

摘要(Abstract)：

目的分析中国汉族人群TAFI基因启动子区-2345 2G/1G与动脉粥样硬化性脑梗死发病的关系。方法选择225例脑梗死(病例组)和184例健康体检者(对照组)为对象,应用等位基因特导性聚合酶链反应分析方法(AS-PCR)检测-2345 2G/1G多态性。结果 TAFI-2345 2G/1G在病例组的1G等位基因频率为42.9%,对照组为50.8%,2组间差异有统计学意义(P=0.024);病例组1G/1G基因型频率为15.1%,对照组为24.5%,2组间差异有统计学意义(P=0.017)。经Logis-tic回归分析,TAFI-2345 1G/1G基因型与脑梗死的发病有独立相关性。结论 TAFI-2345 2G/1G多态性与动脉粥样硬化性脑梗死的发病有关联,1G/1G基因型可能使脑梗死患病风险降低。

关键词(KeyWords)： 凝血酶激活的纤溶抑制物(TAFI);脑梗死;基因多态性

Abstract:

Keywords:

基金项目(Foundation): 2005年教育部留学回国人员科研启动基金,教外司留[2005]546号1

作者(Authors): 陈煜森;曾志良;林智君;冼文川;钟望涛;赵斌;许志恩;

参考文献(References)：

• [1]Flossmann E,Schulz UG,Rothwell PM.Systematic review of methods and results of studies of the genetic epidemiology of is-chemic stroke[J].Stroke,2004,35,212-227.
• [2]Dichgans M.Genetics of ischaemic stroke[J].Lancet Neurol,2007,6:149-161.
• [3]Jerrard-Dunne P,Cloud G,Hassan A,et al.Evaluating the genetic component of ischemic stroke subtypes:a family histo-ry study[J].Stroke,2003,34:1364-1369.
• [4]Stephanie Debette,Sudha Seshadri.Genetics of atherothrom-botic and lacunar stroke[J].Circulation Cardiovascular Genet-ics,2009,2:191-198.
• [5]Bajzar L,Morser J,Nesheim M,et al.TAFI,or plasma pro-carboxypeptidase B,couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex[J].J Biol Chem,1996,271:16603-16608.
• [6]Milji P,Heylen E,Willemse J,et al.Thrombin activatable fi-brinolysis inhibitor(TAFI):a molecular link between coagula-tion and fibrinolysis[J].Srp Arh Celok Lek,2010,138(Sup-pl)1:74-78.
• [7]Mishra N,Vercauteren E,Develter J,et al.Identification and characterisation of monoclonal antibodies that impair the acti-vation of human thrombin activatable fibrinolysis inhibitor through different mechanisms[J].Thromb Haemost,2011,106(1):90-101.
• [8]何芳梅,陈煜森.TAFI基因编码区291C/T的多态性与脑梗死的相关性研究[J].中华神经医学杂志,2009,8(3):254-257
• [9]Henry M,Aubert H,Morange P,et al.Identification of poly-morphisms in the promoter and the3'region of the TAFI gene:evidence that plasma TAFI antigen levels are strongly geneti-cally controlled[J].Blood,2001,97(7):2053-2058.
• [10]Frere C,Tregouet DA,Morange PE,et al.Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study[J].Blood,2006,108(5):1562-1568.
• [11]Leebeek FW,Goor MP,Guimaraes AH,et al.High func-tional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke[J].J Thromb Haemost,2005,3(10):2211-8.
• [12]Boffa MB,Hamill JD,Bastajian N,et al.A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor[J].J Biol Chem,2002,277(28):25329-36.
• [13]Franco RF,Fagundes MG,Morange PE,et al.Identification of polymorphisms in the5'-untranslated region of the TAFI gene:relationship with plasma TAFI levels and risk of venous thrombosis[J].Haematologica,2001,86(5):510-517.
• [14]Boffa MB,Koschinsky ML.Curiouser and curiouser:recent advances in measurement of thrombin-activatable fibrinolysis inhibitor(TAFI)and in understanding its molecular genetics,gene regulation,and biological roles[J].Clin Biochem,2007,40(7):431-442.
• [15]Ladenvall C,Gils A,Jood K,et al.Thrombin activatable fi-brinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene var-iation[J].Arterioscler Thromb Vasc Biol,2007,27(4):955-962.